Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific

References

• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–82.
   PubMed Web of Science ®Google Scholar
• Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolysing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:3198–202.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306–25.
   PubMed Web of Science ®Google Scholar
• Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009;8:1325–7.
   Google Scholar
• Le Hello S, Falcot V, Lacassin F, Baumann F, Nordmann P, Naas T. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in New Caledonia. Clin Microbiol Infect 2008;14:977–81.
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128–40.
   PubMed Web of Science ®Google Scholar
• Esen S, Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis 2004;36:144–8.
   PubMed Web of Science ®Google Scholar
• Héritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:4174–9.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Standard M100-S16. Performance standards for antimicrobial susceptibility testing. 16^th Informational supplement. Wayne, PA: CLSI; 2006.
   Google Scholar
• Van Looveren M, Goossens H; ARPAC steering group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684–704.
   PubMed Web of Science ®Google Scholar
• Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo, . Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003;41:3403–6.
   PubMed Web of Science ®Google Scholar
• Coelho JM, Turton JF, Kaufmann ME, Glover J, Woodford N, Warner M, . Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006;44: 3623–7.
   PubMed Web of Science ®Google Scholar
• Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, . Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J Clin Microbiol 2005;43:2241–5.
   PubMed Web of Science ®Google Scholar
• Srinivasan VB, Rajamohan G, Pancholi P, Stevensen K, Tadesse D, Patchanee P, . Genetic relatedness and mole cular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA. Ann Clin Microbiol Antimicrob 2009;8:21.
   PubMed Web of Science ®Google Scholar
• Niumsup PR, Boonkerd N, Tansawai U, Tiloklurs M. Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand. Jpn J Infect Dis 2009;62:152–4.
   PubMed Web of Science ®Google Scholar
• Mansour W, Poirel L, Bettaieb D, Bouallegue O, Boujaafar N, Nordmann P. Dissemination of OXA-23-producing and carbapenem-resistant Acinetobacter baumannii in a University Hospital in Tunisia. Microb Drug Resist 2008;14:289–92.
   PubMed Web of Science ®Google Scholar
• Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005;43:4826–9.
   PubMed Web of Science ®Google Scholar
• Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, . Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010;5:e9947.
   PubMed Web of Science ®Google Scholar
• Lee SO, Kim NJ, Choi SH, Kim TH, Chung JW, Woo JH, . Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case–control study. Antimicrob Agents Chemother 2004;48:224–8.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care 2006;10:R48.
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, . The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006;64: 282–7.
   PubMed Web of Science ®Google Scholar
• Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, . Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008;27: 607–12.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 2007;26:857–68.
   PubMed Web of Science ®Google Scholar
• Kopterides P, Koletsi PK, Michapoulos A, Falagas ME. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates. Int J Antimicrob Agents 2007; 30:409–14.
   PubMed Web of Science ®Google Scholar